Day: March 20, 2023

ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to improve patient outcomes in critical care settings, today reported its financial results for the year ended December 31, 2022. “Significant developmental strides were made during 2022, with our IL-6 clinical study data affirming the potential of Bluejay’s Symphony System to be a rapid and precise testing platform for near-patient management in critical care settings,” said Neil Dey, CEO of Bluejay Diagnostics. “Recent positive feedback from the FDA indicated an expansion of our clinical study would be necessary to support our planned de novo submission, extending our anticipated submission timeline to the first half...

– Executed income generating license agreement with Lineage Cell Therapeutics to develop gene-edited induced pluripotent stem cell (iPSC)-derived therapies for multiple neurology indications – Entered into a sublease agreement with Bristol Myers Squibb to occupy 45,000 sq. ft. of lab and office space at Cambridge Crossing development in Cambridge, Massachusetts – Appointed Matt Angel, Ph.D. as Chief Executive Officer and President CAMBRIDGE, Mass., March 20, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced financial results for the quarter and year ended December 31, 2022 and provided a business update. “2022 was a transformational...

SHAKOPEE, Minn., March 20, 2023 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today reported financial results for the fourth quarter and full year ended December 31, 2022. ($ in thousands, except per share data and percentages)    Three Months Ended December 31,   Twelve Months Ended December 31,    2022   2021   Change(3)   2022   2021   Change  Net revenues(2) $13,119   $13,955   -6.0%   $66,824   $60,400   10.6%                           Net income(2) $1,063   $6,620   -83.9%   $7,513   $11,798   -36.3%                           Adjusted EBITDA(3) $2,687   $3,360   -20.0%   $15,141   $13,471   12.4%                           Basic EPS $0.22   $1.38   -84.1%   $1.55   $2.47   -37.2%  Diluted EPS $0.22   $1.37   -83.9%   $1.54   $2.44   -36.9%(1) Financial...

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights:Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests. Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue of $12.8 million for the fourth quarter of 2022. John Aballi, President and CEO, joined the Company in the fourth quarter of 2022 and implemented a new strategy focused on reducing cash burn and driving ASP and GM improvement to ultimately reach profitability...

Receives $5.0 million from private convertible note offering Scottsdale, Ariz., March 20, 2023 (GLOBE NEWSWIRE) — via InvestorWire — Cerberus Cyber Sentinel Corporation (“Cerberus Sentinel” or the “Company”) (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider, based in Scottsdale, Ariz., today announced certain preliminary estimated financial information as of and for the quarter and fiscal year ended December 31, 2022. The preliminary estimated financial information has been prepared by, and is the responsibility of, the Company’s management. Semple, Marchal & Cooper, LLP, the Company’s independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to the preliminary estimated financial information provided below. The Company’s...

Press release 2022 annual resultsA year of major developmentsSubstantial increase in operating income Dijon, 20 March 2023, 8.00 p.m. CROSSJECT (ISIN: FR0011716265; Ticker: ALCJ), a specialty pharma company that is developing and will soon be marketing a portfolio of drugs for use in emergency situations (epilepsy, allergic shock, overdose, asthma attack, adrenal insufficiency, etc.), presents its annual results for 2022. “In 2022, Crossject experienced a truly unprecedented year in its history. The growth embedded in contracts signed to date offers unique visibility and marks the turning point we have been waiting for. Optimising our resources to support Crossject’s ramp-up is now our priority, along the lines of the non-dilutive financing we have implemented. Thanks to the efforts of all our teams and the support of our shareholders,...

MONTREAL, March 20, 2023 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the second quarter and the six months ended January 31, 2023. “Our results for this reporting period, while lower than year ago, were above expectations since many of our customers were drawing down prior year’s inventories faster than we forecasted. While revenues were down 6% in the period, they were up 31% from the same period in fiscal 2021. We now expect that revenues, while lower than the exceptional 2022 fiscal year, to be significantly higher than fiscal year 2021,” said Paul Baehr, IBEX President & CEO. “The engine for this growth is the underlying increasing demand and market penetration of our major customers in the high-growth, hemostasis-rapid-testing market segment”. Note:...